Testing FCN-159 for children with LCH that returned
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 16 years
- Diagnosis of Langerhans cell histiocytosis (LCH) confirmed by a central lab
- Must have received at least one prior treatment for LCH (like vinblastine and steroids) or had severe side effects from that treatment
- LCH must be refractory (not responding) or relapsed (came back after treatment)
- Must have LCH lesions that can be measured on a PET scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
This trial is testing a new targeted pill (luvometinib) alone or with another drug (cytarabine) for people with Langerhans cell histiocytosis that needs whole-body treatment. The goal is to see if the new approach can shrink or control the disease.
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
Hear when a new Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.